These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15123038)

  • 1. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.
    Feldmann M; Brennan FM; Williams RO; Woody JN; Maini RN
    Best Pract Res Clin Rheumatol; 2004 Feb; 18(1):59-80. PubMed ID: 15123038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
    Gerlag DM; Tak PP
    Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Embracing novel cytokines in RA - complexity grows as does opportunity!
    Hueber AJ; Asquith DL; McInnes IB; Miller AM
    Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):479-87. PubMed ID: 20732646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulators of cytokine signalling in rheumatoid arthritis.
    Rahman A
    Rheumatology (Oxford); 2007 Dec; 46(12):1745-6. PubMed ID: 17986480
    [No Abstract]   [Full Text] [Related]  

  • 7. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF-induced lupus.
    Williams EL; Gadola S; Edwards CJ
    Rheumatology (Oxford); 2009 Jul; 48(7):716-20. PubMed ID: 19416947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What have we learnt from targeted anti-TNF therapy?
    Feldmann M; Williams RO; Paleolog E
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i97-99. PubMed ID: 19995756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Celis R; Moll C; Izquierdo E; Marsal S; Sanmartí R; Palacín A; Lora D; de la Cruz J; Pablos JL
    Ann Rheum Dis; 2009 May; 68(5):751-6. PubMed ID: 18495732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL; Gause A
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology.
    Patten C; Bush K; Rioja I; Morgan R; Wooley P; Trill J; Life P
    Arthritis Rheum; 2004 Oct; 50(10):3334-45. PubMed ID: 15476226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of disease-modifying antirheumatic drug treatment on the expression of RANKL and osteoprotegerin in synovial tissue: comment on the article by Haynes et al.
    Catrina AI; Klareskog L
    Arthritis Rheum; 2008 Nov; 59(11):1685; author reply 1685-6. PubMed ID: 18975354
    [No Abstract]   [Full Text] [Related]  

  • 15. The TNF-alpha transgenic mouse model of inflammatory arthritis.
    Li P; Schwarz EM
    Springer Semin Immunopathol; 2003 Aug; 25(1):19-33. PubMed ID: 12904889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab treatment of rheumatoid arthritis.
    Maini SR
    Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents.
    Russell AS; Maksymowych WP; de Silva M
    Ann Rheum Dis; 2005 Dec; 64(12):1807. PubMed ID: 16284357
    [No Abstract]   [Full Text] [Related]  

  • 19. Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium.
    Bramlage CP; Kaps C; Ungethüm U; Bramlage P; Koziolek M; Wessels J; Krenn V; Pruss A; Müller GA; Strutz F; Burmester GR; Häupl T
    Scand J Rheumatol; 2008; 37(6):401-9. PubMed ID: 18830904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers.
    Ferraccioli G; Gremese E
    Autoimmun Rev; 2004 Jun; 3(4):261-6. PubMed ID: 15246021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.